To evaluate patient-reported health-related quality-of-life (QoL) in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2−) advanced/metastatic breast cancer (ABC) treated with palbociclib in the longitudinal real-world study, POLARIS. The gene discussed is NR4A1; the disease is aneurysmal bone cyst.